协日嘎四味汤散联合柴芍六君汤对原发性肝癌微创消融术后的疗效观察  

Observation on the Efficacy of XieZhiga SiWei TangSan Combined with ChaiShao LiuJun Tang in Primary Hepatocellular Carcinoma after Minimally Invasive Ablation Surgery

作　　者：李晟 蔡小亮 卢诗艺 林丽静 陈晓晖 王心怡 LI Sheng;CAI Xiao-liang;LU Shi-yi;LIN Li-jing;CHEN Xiao-hui;WANG Xin-yi(Fuzhou Hospital of Traditional Chinese Medicine,Fuzhou 350001,China;Fujian University of Traditional Chinese Medicine,Fuzhou 350000,China)

机构地区：[1]福建中医药大学附属福州中医院,福建福州350001 [2]福建中医药大学,福建福州350000

出　　处：《海峡药学》2024年第8期87-91,共5页Strait Pharmaceutical Journal

基　　金：福建中医药大学校管临床专项资助(№XB2021129);福州市中医院人才培养项目(№榕中医人〔2022〕3号及83号)。

摘　　要：目的探讨协日嘎四味汤散联合加味柴芍六君汤对原发性肝癌微创消融术后患者的疗效及安全性。方法本研究纳入原发性肝癌患者共70例,按相同男女比例随机分为对照组和观察组,每组各35例。微创消融术后1周,对照组给予常规治疗,观察组给予协日嘎四味汤散联合加味柴芍六君汤进行治疗,疗程为一个月。通过检测谷丙转氨酶(Alanine transaminase,ALT)、谷草转氨酶(Aspartate Transaminase,AST)、碱性磷酸酶(Alkaline phosphatase,ALP)、直接胆红素(Direct Bilirubin,DBIL)和血清甲胎蛋白(Alpha-fetoprotein,AFP)等分子对肝功能以及肝癌发展进行评估;采用肝癌生命质量测定量表(Quality of Life in Liver Cancer Measurement Scale,QOL-LC)评估患者生存质量;采用中医症状积分量表评估症状严重程度。结果治疗后,观察组在血清功能相关指标方面表现出显著改善,具体表现为ALT、AST、ALP、DBIL和AFP含量显著低于对照组(P<0.05)。在生命质量评分方面,观察组在躯体功能、症状/副作用和社会功能评分上均显著优于对照组(P<0.05)。在中医症状分级方面,观察组中医症状分级为轻度和中度的患者占比明显多于对照组(P<0.05)。在安全性评估中,观察组出现不良反应的患者数亦显著少于对照组(P<0.05)。结论本研究表明了协日嘎四味汤散联合加味柴芍六君汤在原发性肝癌微创消融术后的治疗中具有一定疗效。OBJECTIVE This study investigates the efficacy and safety of XieZhiGa SiWei TangSan combined with ChaiShao LiuJun Tang in postoperative patients.METHODS A total of 70 patients with primary liver cancer were included in this study,and were randomly divided into the control group and the observation group according to the same proportion of men and women,with 35 cases in each group.One week after minimally invasive ablation,the control group was given conventional treatment,and the observation group was given XieZhiGa SiWei TangSan combined with JiaWei ChaiShao LiuJun Tang for treatment.The course of treatment is one month.Alanine transaminase(ALT),Aspartate transaminase(AST),Alkaline phosphatase(ALP),Direct Bilirubin(DBIL)and Serum Alpha-fetoprotein(AFP)molecules were used to assess liver function and hepatocellular carcinoma progression;Quality of Life in Liver Cancer Measurement Scale(QOL-LC)was used to assess the quality of survival of patients.RESULTS After treatment,the observation group demonstrated significant improvement in serum function-related indexes,as evidenced by significantly lower levels of ALT,AST,ALP,DBIL and AFP than the control group(P<0.05).In terms of quality of life scores,the observation group was significantly better than the control group in terms of somatic function,symptoms/side effects and social function scores(P<0.05).In terms of TCM symptom grading,the observation group had significantly more patients with mild and moderate TCM symptom grading than the control group(P<0.05).In the safety assessment,the number of patients with adverse reactions in the observation group was also significantly lower than that in the control group(P<0.05).CONCLUSION This study demonstrated the significant efficacy of XieZhiGa SiWei TangSan combined with ChaiShao LiuJun Tang in the treatment of primary hepatocellular carcinoma after minimally invasive ablation.

关 键 词：原发性肝癌 微创消融 协日嘎四味汤散 柴芍六君汤 

分 类 号：R969.4[医药卫生—药理学]